“Newron is expected to initiate a Phase III randomized, double-blind, one-year trial in H1 2025 that will compare evenamide to placebo as add-on treatment in at least 600 patients with treatment-resistant schizophrenia (TRS). The primary efficacy endpoint will be change from baseline in the Positive and Negative Syndrome Scale (PANSS) scores at 12 weeks. Following this initial period, subjects will continue on their assigned treatment until week 52, for demonstration of long-term efficacy and safety and tolerability of evenamide. Newron continues to pursue further development opportunities for evenamide in other territories.”
Related topics
Topic | Replies | Views | Activity | |
---|---|---|---|---|
Eisai unit hands over $46M for Japanese rights to Newron’s schizophrenia add-on | 1 | 73 | December 13, 2024 | |
Newron presents H1 2024 results and provides business update | 0 | 42 | September 20, 2024 | |
Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia | 5 | 654 | June 9, 2022 | |
Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA | 3 | 340 | January 9, 2020 | |
Evenamide could be a potential breakthrough treatment in the management of treatment-resistant schizophrenia (TRS) patients | 2 | 403 | February 17, 2023 |